Revvity vs 10x Genomics: revenue, profit, margins and growth compared
Revvity brought in $2.9B of revenue in fiscal 2025, 10x Genomics $642.8M in fiscal 2025. Revenue changed by +3.7% at Revvity and +5.2% at 10x Genomics on the year before, so 10x Genomics grew faster. Revvity kept 8.4% of its revenue as net profit, 10x Genomics -6.8%. Free cash flow was $509.4M at Revvity and $130.1M at 10x Genomics.
Fiscal years as each company reports them; the two may end in different months.
Questions about Revvity and 10x Genomics
Which is bigger by revenue, Revvity or 10x Genomics?
Revvity is bigger by revenue: $2.9B in fiscal 2025, against $642.8M for 10x Genomics in fiscal 2025.
Which keeps more of its revenue as profit, Revvity or 10x Genomics?
Revvity had a net margin of 8.4% in fiscal 2025; 10x Genomics had -6.8% in fiscal 2025.
Which grew revenue faster, Revvity or 10x Genomics?
In their latest fiscal years revenue changed by +3.7% at Revvity and +5.2% at 10x Genomics.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.